Artificial intelligence (AI)-powered cancer diagnostics firm Ibex Medical Analytics, and pathology laboratory CorePlus have collaborated on over 10,000 diagnosed cases of cancer using Galen, Ibex's AI-powered diagnostics platform. In a significant boost to patient outcomes, pathologists used AI-driven insights from Galen to correct the diagnosis of over 150 patients.
CorePlus was the first laboratory in North America to deploy an AI-powered pathology solution, implementing Ibex's Galen Prostate for before-sign-out quality control, and then expanded its capabilities to include Galen Breast in the diagnosis of breast biopsies. Following the successful rollout of both technologies, used to analyse more than 125,000 pathology slides, CorePlus has expanded deployment and its pathologists now use Galen during primary diagnosis, benefiting from AI-powered insights for triage, detection of cancer and other morphologic features, grading and reporting. Moreover, the expansion also drives efficiency gains as Galen helps to streamline laboratory processes and reporting.
"Ibex's robust AI platform has brought greater confidence to our pathologists, providing continuously accurate insights and enabling us to support referring urologists with more accurate and objective diagnostic reports," said Juan C Santa Rosario, MD, Chief Medical Officer at CorePlus. "Our use of Ibex's technology in primary diagnosis enables our pathologists to operate more efficiently at a greater scale and helps us significantly reduce turnaround time to keep up with growing demand."
Galen supports CorePlus pathologists in the diagnosis of breast and prostate biopsies by helping them identify cancer, determine the cancer grading and subtype, and detect multiple other malignant and non-malignant morphological features. Galen also helps pathologists prioritise cases and rapidly access areas of interest, as well as automating tasks such as reporting and tumour measurement. Galen is the most widely deployed AI technology in pathology and is used as part of everyday clinical practice at laboratories, hospitals and health systems worldwide.
"Ibex is driving the future of cancer diagnosis, providing pathologists with the best tools to deliver accurate and timely diagnosis powered by AI," said Joseph Mossel, Co-Founder and CEO of Ibex Medical Analytics. "I am delighted to see CorePlus leading the way in adoption, demonstrating how patient outcomes can be improved through the implementation of AI for primary diagnosis. We remain focused on bringing our AI platform to laboratories around the world to help pathologists reach zero misdiagnoses in cancer, and CorePlus demonstrates how this is achievable."
